Lawrence Otto Klein
CIK: 0001762583
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (21 total)
- Nov 2, 2026ORKA
Oruka Therapeutics, Inc.
Sale(S)Direct300 shares at avg. $98.40$30K - Nov 2, 2026ORKA
Oruka Therapeutics, Inc.
Exercise(M)Direct25K shares at avg. $7.80$195K - Nov 2, 2026ORKA
Oruka Therapeutics, Inc.
Sale(S)Direct6.5K shares at avg. $94.77$613K - Nov 2, 2026ORKA
Oruka Therapeutics, Inc.
Sale(S)Direct15K shares at avg. $95.64$1.4M - Nov 2, 2026ORKA
Oruka Therapeutics, Inc.
Sale(S)Direct2.4K shares at avg. $96.70$236K - Nov 2, 2026ORKA
Oruka Therapeutics, Inc.
Sale(S)Direct756 shares at avg. $97.45$74K - Oct 1, 2026ORKA
Oruka Therapeutics, Inc.
Sale(S)Direct200 shares at avg. $84.78$17K - Oct 1, 2026ORKA
Oruka Therapeutics, Inc.
Exercise(M)Direct25K shares at avg. $7.80$195K - Oct 1, 2026ORKA
Oruka Therapeutics, Inc.
Sale(S)Direct16.2K shares at avg. $83.40$1.4M - Oct 1, 2026ORKA
Oruka Therapeutics, Inc.
Sale(S)Direct8.6K shares at avg. $84.03$719K - Sep 15, 2026ORKA
Oruka Therapeutics, Inc.
Sale(S)Direct2.5K shares at avg. $95.71$235K - Sep 1, 2026ORKA
Oruka Therapeutics, Inc.
Sale(S)Direct63.6K shares at avg. $91.90$5.8M - Sep 1, 2026ORKA
Oruka Therapeutics, Inc.
Exercise(M)Direct75K shares at avg. $7.80$585K - Sep 1, 2026ORKA
Oruka Therapeutics, Inc.
Sale(S)Direct6.6K shares at avg. $90.79$600K - Sep 1, 2026ORKA
Oruka Therapeutics, Inc.
Sale(S)Direct4.8K shares at avg. $92.44$444K - Jun 15, 2026ORKA
Oruka Therapeutics, Inc.
Sale(S)Direct1.7K shares at avg. $69.69$120K - Jun 9, 2026JBIO
Jade Biosciences, Inc.
Award(A)DirectStock Option (Right to Buy)
34.8K shares- - Mar 16, 2026ORKA
Oruka Therapeutics, Inc.
Sale(S)Direct1.7K shares at avg. $41.30$71K - Jan 23, 2026ORKA
Oruka Therapeutics, Inc.
Award(A)Direct76.7K shares- - Apr 29, 2025JBIO
Jade Biosciences, Inc.
Award(A)DirectStock Option (Right to Buy)
23K shares- - Jan 22, 2025ORKA
Oruka Therapeutics, Inc.
Award(A)DirectEmployee Stock Option (right to buy)
230K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Nov 2, 2026 |  ORKA Oruka Therapeutics, Inc. | Sale(S) | 300 | $98.40 | $29,521 | Direct |
| Nov 2, 2026 | ORKA Oruka Therapeutics, Inc. | Exercise(M) | 25,000 | $7.80 | $195,000 | Direct |
| Nov 2, 2026 | ORKA Oruka Therapeutics, Inc. | Sale(S) | 6,466 | $94.77 | $612,794 | Direct |
| Nov 2, 2026 | ORKA Oruka Therapeutics, Inc. | Sale(S) | 15,036 | $95.64 | $1,437,987 | Direct |
| Nov 2, 2026 | ORKA Oruka Therapeutics, Inc. | Sale(S) | 2,442 | $96.70 | $236,147 | Direct |
| Nov 2, 2026 | ORKA Oruka Therapeutics, Inc. | Sale(S) | 756 | $97.45 | $73,676 | Direct |
| Oct 1, 2026 | ORKA Oruka Therapeutics, Inc. | Sale(S) | 200 | $84.78 | $16,956 | Direct |
| Oct 1, 2026 | ORKA Oruka Therapeutics, Inc. | Exercise(M) | 25,000 | $7.80 | $195,000 | Direct |
| Oct 1, 2026 | ORKA Oruka Therapeutics, Inc. | Sale(S) | 16,246 | $83.40 | $1,354,882 | Direct |
| Oct 1, 2026 | ORKA Oruka Therapeutics, Inc. | Sale(S) | 8,554 | $84.03 | $718,755 | Direct |
| Sep 15, 2026 | ORKA Oruka Therapeutics, Inc. | Sale(S) | 2,452 | $95.71 | $234,681 | Direct |
| Sep 1, 2026 | ORKA Oruka Therapeutics, Inc. | Sale(S) | 63,596 | $91.90 | $5,844,237 | Direct |
| Sep 1, 2026 | ORKA Oruka Therapeutics, Inc. | Exercise(M) | 75,000 | $7.80 | $585,000 | Direct |
| Sep 1, 2026 | ORKA Oruka Therapeutics, Inc. | Sale(S) | 6,604 | $90.79 | $599,556 | Direct |
| Sep 1, 2026 | ORKA Oruka Therapeutics, Inc. | Sale(S) | 4,800 | $92.44 | $443,691 | Direct |
| Jun 15, 2026 | ORKA Oruka Therapeutics, Inc. | Sale(S) | 1,729 | $69.69 | $120,494 | Direct |
| Jun 9, 2026 |  JBIO Jade Biosciences, Inc. | Award(A) Stock Option (Right to Buy) | 34,843 | - | - | Direct |
| Mar 16, 2026 | ORKA Oruka Therapeutics, Inc. | Sale(S) | 1,729 | $41.30 | $71,408 | Direct |
| Jan 23, 2026 | ORKA Oruka Therapeutics, Inc. | Award(A) | 76,700 | - | $0 | Direct |
| Apr 29, 2025 | JBIO Jade Biosciences, Inc. | Award(A) Stock Option (Right to Buy) | 23,017 | - | - | Direct |
| Jan 22, 2025 | ORKA Oruka Therapeutics, Inc. | Award(A) Employee Stock Option (right to buy) | 230,000 | - | - | Direct |
1-21 of 21 transactions
About Klein Lawrence Otto
Klein Lawrence Otto (SEC CIK 0001762583) files insider reports with the SEC as Chief Executive Officer of Oruka Therapeutics, Inc. (ORKA) and Director of Jade Biosciences, Inc. (JBIO).
Signal8 holds 12 ownership filings by Klein Lawrence Otto (2 Form 3, 10 Form 4), filed between Sep 6, 2024 and Nov 2, 2026. Those filings report 21 transactions, from Jan 22, 2025 to Nov 2, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Klein Lawrence Otto's filings is in MENLO PARK, CA.
Recent filings by Klein Lawrence Otto
- Nov 2, 2026: Open-market sale of ORKA shares (Form 4, code S).
- Nov 2, 2026: Option exercise of ORKA shares (Form 4, code M).
- Nov 2, 2026: Open-market sales of ORKA shares (4 lines, Form 4, code S).
- Oct 1, 2026: Open-market sale of ORKA shares (Form 4, code S).
- Oct 1, 2026: Option exercise of ORKA shares (Form 4, code M).
Other insiders filing for Oruka Therapeutics, Inc. (ORKA)
- Quinlan Paul T, General Counsel
- Goncalves Joana, Chief Medical Officer
- Agarwal Arjun, Senior Vice President, Finance
- Sandler Laura Lee, Chief Operating Officer
- Edwards Larry Todd, Chief Commercial Officer
- Fairmount Funds Management LLC, Director